Journal article
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
Abstract
PURPOSE: To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended dose for phase II studies, and to explore its efficacy. We assessed toxicities and explored the activity of the drug combination exclusively in patients with malignant pleural mesothelioma (MPM). The pharmacokinetics of both agents was investigated.
PATIENTS AND METHODS: Twenty-seven patients (23 male, four female) …
Authors
Hughes A; Calvert P; Azzabi A; Plummer R; Johnson R; Rusthoven J; Griffin M; Fishwick K; Boddy AV; Verrill M
Journal
Journal of Clinical Oncology, Vol. 20, No. 16, pp. 3533–3544
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
August 15, 2002
DOI
10.1200/jco.2002.10.073
ISSN
0732-183X